(E)-N-hydroxy-5-phenylpent-4-enamide | 1159991-80-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-N-hydroxy-5-phenylpent-4-enamide
• 英文别名: (4E)-N-hydroxy-5-phenylpent-4-enamide
• CAS: 1159991-80-6
• 化学式: C₁₁H₁₃NO₂
• 分子量: 191.23
• InChiKey: KGHGJVPMHXTGOC-XBXARRHUSA-N

物化性质

• 密度：
  1.146±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-N-hydroxy-5-phenylpent-4-enamide 在 C₃₄H₃₀Cl₄F₁₂Ir₂ 、 sodium acetate 、 双三氟甲烷磺酰亚胺银盐 作用下， 以 二氯甲烷 为溶剂， 反应 12.5h， 生成 (R/S)-{(R/S)-5-oxopyrrolidin-2-yl}(phenyl)methyl acetate
  参考文献：
  名称：

  Stereodefined Access to Lactams via Olefin Difunctionalization: Iridium Nitrenoids as a Motif of LUMO-Controlled Dipoles

  摘要：

  Reported herein is a general platform of a stereodefined access to gamma-lactams via Cp*Ir-catalyzed olefin difunctionalization, where in situ generated Ir-nitrenoid is utilized as a key motif of 1,3-dipoles to enable amido transfer in a syn-selective manner. Computational studies suggested that the stereodefined process can be attributed to the proposed working mode of concerted [3 + 2] cyclization. Frontier molecular orbital (FMO) analysis implied that a low-lying lowest unoccupied molecular orbital (LUMO) of the Ir-imido fragment engages in the olefin interaction. Mechanistic understanding on the nitrene transfer process led us to develop mild catalytic protocols of stereoselective difunctionalization of alkenyl dioxazolones to furnish alpha-(haloalkyl)- or (oxyalkyl)lactam products which are of high synthetic and medicinal utility. Product stereochemistry (threo and erythro) was found to be designated by the olefin geometry (E/Z) of substrates.

  DOI：

  10.1021/jacs.9b04317
• 作为产物：
  描述：

  5-苯基-4-戊烯酸 在 盐酸羟胺 作用下， 以 四氢呋喃 为溶剂， 生成 (E)-N-hydroxy-5-phenylpent-4-enamide
  参考文献：
  名称：

  未活化烯烃的配体控制的 Ir 催化区域发散氧化

  摘要：

  未活化烯烃的分子内 Ir(III) 催化区域发散氧化胺化提供有价值的 γ-内酰胺、γ-内酯和 δ-内酰胺。区域选择性由电子可调的环戊二烯基 Ir(III)-络合物控制，该络合物能够通过 5-exo 或 6-endo 途径进行氧胺化。在机制方面，我们提出了一种源自 Ir(V) 氮烯介导的氮丙啶化的高反应性 [3.1.0] 自行车中间体，作为合成 γ-内酰胺的关键中间体。

  DOI：

  10.1021/jacs.9b06366

文献信息

• Tethered Aminohydroxylation (TA) Reaction of Amides
  作者：Timothy J. Donohoe、Cedric K. A. Callens、Amber L. Thompson

  DOI：10.1021/ol900631y

  日期：2009.6.4

  The first examples of amide-tethered aminohydroxylation reactions, catalyzed by osmium, showing that the use of N−O-based reoxidants are essential for success, are reported. The system that is described is compatible with a variety of different alkene substitution patterns and ring sizes and works with low loadings in both cyclic and acyclic systems. The levels of diastereoselectivity that were observed

  据报道，催化的酰胺束缚的氨基羟基化反应的第一个例子表明，使用基于N-O的再氧化剂对成功至关重要。所描述的系统与多种不同的烯烃取代方式和环大小兼容，并且在环状和非环状系统中均以低负荷运行。对于在有机合成中使用立体选择性TA反应而言，对于在烯丙基和烯丙基位置上的取代基都观察到的非对映选择性水平很好。
• CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS
  申请人：Watkins Clare J.

  公开号：US20100249197A1

  公开（公告）日：2010-09-30

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q 1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR 1 C(═O)— and —C(═O)NR 1 —; R 1 is an amido substituent; and, Q 2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psorias

  本发明涉及某些活性碳酰胺酸化合物，其抑制HDAC活性，其具有式（1），其中：A是芳基基团；Q1是至少具有2个碳原子骨架的芳基前导基团；J是选择自以下的酰胺连接：—NR1C(═O)—和—C(═O)NR1—；R1是酰胺取代基；以及Q2是酸前导基团；以及其药学上可接受的盐、溶剂化物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包括这种化合物的制药组合物，以及使用这种化合物和组合物，在体内外抑制HDAC，例如抑制增殖性疾病，如癌症和银屑病。
• Iron-Catalyzed Intra-intermolecular Aminoazidation of Alkenes
  作者：Sandra Abi Fayssal、Alessandro Giungi、Farouk Berhal、Guillaume Prestat

  DOI：10.1021/acs.oprd.9b00400

  日期：2020.5.15

  An intra-intermolecular iron-catalyzed aminoazidation of non-activated alkenes is reported for the preparation of imidazolidinone, oxazolidinone, and pyrrolidinone derivatives. The method uses cheap and abundant iron as a catalyst and commercially available TMSN3 as an azide source. This domino process allows, in a single operating step, for a ring-closure that generates an aza-heterocycle and the introduction of an azido appendage tethered to the heterocycle. The conditions developed offer a sustainable alternative method for the preparation of unsymmetrical vicinal diamine compounds.
• US7569724B2
  申请人：——

  公开号：US7569724B2

  公开（公告）日：2009-08-04
• US7880020B2
  申请人：——

  公开号：US7880020B2

  公开（公告）日：2011-02-01